These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30565573)

  • 1. [Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?].
    Bersanelli M; Buti S; De Giorgi U; Di Maio M; Giannarelli D; Banna GL
    Recenti Prog Med; 2018 Nov; 109(11):540-546. PubMed ID: 30565573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
    Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
    Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.
    Zhang N; Tu J; Wang X; Chu Q
    Immunotherapy; 2019 Apr; 11(5):429-441. PubMed ID: 30698054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
    Bersanelli M; Giannarelli D; De Giorgi U; Pignata S; Di Maio M; Clemente A; Verzoni E; Giusti R; Di Napoli M; Aprile G; Ermacora P; Catino A; Scotti V; Mazzoni F; Guglielmini PF; Veccia A; Maruzzo M; Rossi E; Grossi F; Casadei C; Ficorella C; Montesarchio V; Verderame F; Rizzo M; Guaitoli G; Fratino L; Accettura C; Mencoboni M; Zustovich F; Baldessari C; Cinieri S; Camerini A; Laera L; Sorarù M; Zucali PA; Guadalupi V; Leonardi F; Tiseo M; Tognetto M; Di Costanzo F; Pinto C; Negrini G; Russo A; Migliorino MR; Filetti M; Buti S;
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 in disease.
    Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough.
    Bersanelli M; Buti S; De Giorgi U; Di Maio M; Giannarelli D; Pignata S; Banna GL
    Crit Rev Oncol Hematol; 2019 Jul; 139():87-90. PubMed ID: 31112887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
    Gill DM; Agarwal N
    Urol Oncol; 2017 Dec; 35(12):676-677. PubMed ID: 29054496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
    Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
    Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.
    Ciudad CJ; Medina Enriquez MM; Félix AJ; Bener G; Noé V
    Immunotherapy; 2019 Apr; 11(5):369-372. PubMed ID: 30786843
    [No Abstract]   [Full Text] [Related]  

  • 20. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.